Marketing, FDA communication, tobacco perceptions and use in addiction treatment

营销、FDA 沟通、烟草认知和成瘾治疗中的使用

基本信息

批准号：
8737829
负责人：
Joseph R Guydish
金额：
$ 76.45万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-30 至 2017-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8737829
关键词：
Address Adolescent Adopted Adult Advertising Advisory Committees Affect Age Alcohol or Other Drugs use American Attitude Awareness Behavior Categories Charge Child Cigarette Clinical Trials Network Collaborations Communication Complex Computer Assisted Data Development Disease Drug abuse Education Enrollment Environment Ethnic Origin Exposure to Family Smoking Prevention and Tobacco Control Act Flavoring Funding Agency Future Goals Government Agencies Growth Health Health Services High Prevalence Income Individual International Interview Label Laws Left Light Low income Marketing Measures Mental Health National Institute of Drug Abuse Online Systems Outcome Patients Perception Persons Population Positioning Attribute Prevalence Public Health Publishing Race Recording of previous events Recruitment Activity Regulation Reporting Research Research Infrastructure Research Priority Risk Role Sales Sampling Services Shapes Smoke Smokeless Tobacco Smoker Smoking Subgroup System Testing Time Tobacco Tobacco Use Cessation Tobacco use United States Food and Drug Administration United States Public Health Service Vulnerable Populations Work addiction authority innovation meetings nicotine replacement prevent programs reduce tobacco use response restricting smoking risk perception smoking prevalence snus social stigma standard measure time use tobacco advertising tobacco control treatment program vapor

项目摘要

DESCRIPTION (provided by applicant): The 2009 Tobacco Control Act charged the FDA with regulating tobacco products in the service of public health. The FDA identified key research priorities, including: understanding the diversity of tobacco products, understanding communications about tobacco products, and understanding tobacco product marketing. Broadening the traditional focus of tobacco control, the FDA calls out "vulnerable populations" in 11 of its 56 research priorities. Over 4 million persons receive some type of addiction treatment annually. In this vulnerable, disenfranchised and stigmatized population, where many receive health services in our public health sector, smoking rates are high (67-75%) and unyielding to prior tobacco control efforts. Because persons in this population are highly likely to smoke, they have high exposure to tobacco marketing and are likely to try, use, and adopt some emerging and potentially modified risk tobacco products. In response to PAR-12-267, the current application will recruit a national stratified random sample of 25 addiction treatment programs, where patients will be recruited to FDA research on tobacco. Patients will be recruited in three annual cross-sectional interview waves (N=1,000 per wave) and, using web-based computer assisted strategies, will be interviewed concerning use of traditional and emerging tobacco products, exposure to FDA communication and tobacco marketing, risk perception related to a range of tobacco products, and tobacco use behavior. The application uses a mixture of measures that are standard, adapted and new measures to test hypotheses that use of any tobacco products remains high over time, that use of modified risk tobacco products increases in this population over time, that exposure to FDA communications and tobacco marketing are differentially associated with level of tobacco risk-perception, and that level of risk perception s differentially associated with efforts to reduce or quit tobacco use in this population. Because this population is where smokers are concentrated, it is also where information identified in FDA priorities is most needed, but least available. The short term goal of this research is to understand use of tobacco products, marketing, messaging, and perceptions associated with those products, and their relation to tobacco use behavior in addiction treatment populations. The long-term goal is to support regulatory activity to reduce tobacco use and tobacco risks in this vulnerable population.

描述（由申请人提供）：2009 年《烟草控制法案》责成 FDA 负责监管烟草产品以服务公众健康。 FDA 确定了关键的研究重点，包括：了解烟草产品的多样性、了解烟草产品的传播以及了解烟草产品的营销。 FDA 扩大了烟草控制的传统重点，在其 56 个研究重点中的 11 个中提到了“弱势群体”。每年有超过 400 万人接受某种类型的成瘾治疗。在这个弱势、被剥夺权利和受到污名化的人群中，许多人在我们的公共卫生部门接受卫生服务，吸烟率很高（67-75%），并且不屈服于先前的烟草控制努力。由于该人群中的人很可能吸烟，因此他们经常接触烟草营销，并且可能尝试、使用和采用一些新兴的和潜在的改良风险烟草产品。为了响应 PAR-12-267，当前的申请将招募 25 个成瘾治疗项目的全国分层随机样本，其中患者将被招募到 FDA 的烟草研究中。将分三轮年度横断面访谈招募患者（每轮 N=1,000 人），并使用基于网络的计算机辅助策略，就传统和新兴烟草产品的使用、接触 FDA 沟通和烟草营销、风险等方面进行访谈与一系列烟草产品和烟草使用行为相关的认知。该申请使用了标准、适应性和新措施的混合措施来测试以下假设：随着时间的推移，任何烟草产品的使用量仍然很高，随着时间的推移，该人群中改良风险烟草产品的使用量会增加，接触 FDA 通信和烟草的情况营销与烟草风险认知水平存在差异性关联，而风险认知水平与该人群减少或戒烟的努力也存在差异性关联。由于这一人群是吸烟者集中的地方，因此也是最需要 FDA 优先事项中确定的信息但又最不可用的地方。这项研究的短期目标是了解烟草产品的使用、营销、信息传递和与这些产品相关的认知，以及它们与成瘾治疗人群中烟草使用行为的关系。长期目标是支持监管活动，以减少这一弱势群体的烟草使用和烟草风险。